Google
QGEN Stock Price & Analysis — Qiagen NV (Healthcare >> Diagnostics & Research)
QGEN FAQ
What is QGEN's P/E ratio?
Qiagen NV (QGEN) currently trades at a P/E ratio of 21.26.
What is QGEN's ROE?
Qiagen NV reports a Return on Equity (ROE) of 12.07%.
What is QGEN's dividend yield?
Qiagen NV offers a dividend yield of 0.00%.
What is QGEN's Quality Score?
Our AI rates QGEN's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy QGEN?
Our AI Timing Score for QGEN is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does QGEN belong to?
Qiagen NV is classified under the Healthcare >> Diagnostics & Research sector on the NYSE exchange
QGEN AI Analysis Summary
Our AI summary for QGEN: Qiagen NV (NYSE), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 21.26, ROE of 12.07%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 41.40
Price
-0.05
(-0.12%)
Day Change
|
|
|---|
QGEN, the overall quality is good ( Quality = 77) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROE is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
52% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
1277
|
| Magic Formula Rank by ROE |
1277
|
| Magic Formula Rank by ROIC |
1588
|
| Price | 41.40 |
| PBV / Sector |
2.57 / -29.69
|
| Earning Per Share | 1.95 |
| PE / Sector |
21.26 / 48.18
|
| PEG or PE/Growth / Sector |
0.19 / 1.64
GREAT
|
| Average 1M Daily Value |
104.24 M
GREAT
|
| Average 1W Daily Value |
68.57 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
72% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:22 |
| Symbol | QGEN |
| Name | QIAGEN NV |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NYSE |
| Listed Shares | 206.25 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8,549.06 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Hulsterweg 82, Venlo, Netherlands, 5912 PL
Phone: 31 77 355 6600
Website: https://www.qiagen.com
Employees: 5,500
Description: Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
